Dr. Mir is a Geriatric Oncology & Clinical Therapeutics T32 Fellow at the University of Chicago. My interests include enhancing clinical trial enrollment of vulnerable populations with cancer, such as adults of advanced age, those with comorbidities, and the functionally impaired. My goal is to expand the evidence base of cancer care in this population by pushing the barriers of current clinical trial designs that limit novel therapies to those considered “fit.” My current research revolves around understanding the role of frailty in novel cancer therapeutic selection and dose, creating a predictive tool for androgen receptor signaling inhibitor-related toxicity, and the use of digital health in monitoring the longitudinal risk of toxicity and frailty in older adults with cancer.
